Peregrine Pharmaceuticals reported $7.11M in Selling and Administration Expenses for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Agenus AGEN:US USD 25.04M 6.93M
Amgen AMGN:US USD 1.47B 181M
AstraZeneca AZN:LN USD 3.53B 174M
Biocryst Pharmaceuticals BCRX:US USD 50.15M 13.23M
Bristol Myers Squibb BMY:US USD 2.27B 336M
Celldex Therapeutics CLDX:US USD 6.6M 68K
Eli Lilly And LLY:US USD 1.64B 29M
GlaxoSmithKline GSK:LN GBP 2.44B 467M
Immunogen IMGN:US USD 42.06M 8.44M
Intrexon XON:US USD 11.51M 1.37M
Karyopharm Therapeutics KPTI:US USD 34.65M 4K
Macrogenics MGNX:US USD 13.67M 1.68M
Mannkind MNKD:US USD 22.1M 543K
Merk MRK:US USD 2.63B 134M
Minerva Neurosciences NERV:US USD 1.88M 959.93K
Newlink Genetics NLNK:US USD 4.48M 567K
Novartis NOVN:VX USD 3.7B 295M
Novavax NVAX:US USD 161.66M 38.79M
Peregrine Pharmaceuticals PPHM:US USD 7.11M 276K
Repligen RGEN:US USD 53.24M 406K
Roche Holding ROG:VX 6.48B 834M
Xencor XNCR:US USD 12.75M 377K